October was the biotech sector's worst month in 2013.
"Worst" is relative in an otherwise unbelievable year for biotech stocks, but as you can see from the chart above, our little corner of the market was beat by the S&P 500 in October.
I probably had something to do with the Catalyst sell off. Acadia Pharmaceuticals (ACAD - Get Report) was the second-best performing stock January through September. And in October: ACAD data by YCharts
Celldex Therapeutics (CLDX - Get Report): Third-best return January through September. Not in October: nd CLDX data by YCharts
Picking up the pattern? Here's Biocryst Pharmaceutics (BCRX - Get Report), fourth best until Octoer: ^NBI data by YCharts
-- Reported by Adam Feuerstein in Boston. Follow Adam Feuerstein on Twitter.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts